Skip to main content

Posts

Showing posts from April 18, 2025

Detection of Avian #Influenza Virus in #Pigeons

Abstract Pigeons (Columba livia) are usually kept as free-ranging or racing birds, and they have direct contact with livestock, poultry, and humans . Therefore, they may have an important role in the ecology of influenza virus among various species. In the present study, we bring together all available sequence data of pigeon avian influenza virus (AIV) from public databases to address the current understanding of the genomic characteristics and emergence of each subtype of AIV in pigeons. Collectively, we identified 658 pigeon AIV strains in 21 countries across the world, which were mainly distributed in Europe, Asia, and North America. H1 (2), H2 (1), H3 (8), H5 (71), H6 (16), H7 (16), H9 (543), and H11 (1) AIV subtypes have been identified in pigeons. In addition, we interrogate features of the H5, H6, H7, and H9 subtypes of pigeon AIV, which are relatively common in pigeons. It is particularly noteworthy that the H5 AIV strains identified in pigeons are all classified as HPAIV. For...

#Liberia - High pathogenicity avian #influenza #H5N1 viruses (poultry) (Inf. with) - Immediate notification

  A poultry farm in Totota, right behind the Lutheran football field in Bong County. Source: WOAH,  https://wahis.woah.org/#/in-review/6432 ____

#USA, Monitoring for Avian #Influenza A(#H5) Virus In #Wastewater (as of April 18 '25)

{Excerpt} Time Period: April 06, 2025 - April 12, 2025 -- H5 Detection :  3 sites ( 0.9% ) -- No Detection :  348 sites ( 99.1% ) -- No samples in last week :  243 sites (...) Source: US Centers for Disease Control and Prevention,  https://www.cdc.gov/bird-flu/h5-monitoring/index.html?cove-tab=0 ____

#Chikungunya virus virus-like particle #vaccine #safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial

Summary Background Adults older than 65 years are at increased risk for atypical presentations of chikungunya disease, as well as for severe outcomes including death. Methods In this phase 3, randomised, double-blind, placebo-controlled, parallel-group trial, adults aged 65 years and older received a single intramuscular dose of Vimkunya (previously chikungunya virus virus-like particle vaccine) or placebo at ten sites in the USA. Participants, clinical site personnel, and the sponsor were masked to individual treatment assignments until all participants had completed their involvement in the trial and the database was cleaned and locked. Baseline and postvaccination chikungunya virus serum neutralising antibody (SNA) titres (NT80) were assessed at selected timepoints. Safety was assessed up to 183 days after dose administration in all participants from the exposed population who provided safety assessment data. This trial is registered with ClinicalTrials.gov, NCT05349617, and is comp...

Estimates of #epidemiological #parameters for #H5N1 #influenza in #humans: a rapid review

Abstract Background   The ongoing H5N1 panzootic in mammals has amplified zoonotic pathways to facilitate human infection . Characterising key epidemiological parameters for H5N1 is critical should it become widespread.  Aim   To identify and estimate critical epidemiological parameters for H5N1 from past and current outbreaks, and to compare their characteristics with human influenza subtypes and the 2003 Netherlands H7N7 outbreak .  Methods   We searched PubMed, Embase, and Cochrane Library for systematic reviews reporting parameter estimates from primary data or meta-analyses. To address gaps, we searched PubMed and Google Scholar for studies of any design providing relevant estimates. We estimated the basic reproduction number for the outbreak in the US and the 2003 Netherlands H7N7 outbreak. In addition we estimated the serial interval for H5N1 using data from previous household clusters in Indonesia . We also applied a branching process model to simulate t...